CY1108786T1 - Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα - Google Patents

Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα

Info

Publication number
CY1108786T1
CY1108786T1 CY20081100999T CY081100999T CY1108786T1 CY 1108786 T1 CY1108786 T1 CY 1108786T1 CY 20081100999 T CY20081100999 T CY 20081100999T CY 081100999 T CY081100999 T CY 081100999T CY 1108786 T1 CY1108786 T1 CY 1108786T1
Authority
CY
Cyprus
Prior art keywords
arylsulfonyl
relevance
preparation
serotonin receptor
medicinal products
Prior art date
Application number
CY20081100999T
Other languages
Greek (el)
English (en)
Inventor
Venkata Satya Nirogi Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Venkata Satya Veerabhadra Vadlamudi Rao
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Publication of CY1108786T1 publication Critical patent/CY1108786T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
CY20081100999T 2002-11-28 2008-09-17 Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα CY1108786T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN884MA2002 2002-11-28
EP03735970A EP1581492B1 (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Publications (1)

Publication Number Publication Date
CY1108786T1 true CY1108786T1 (el) 2014-04-09

Family

ID=40184827

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100999T CY1108786T1 (el) 2002-11-28 2008-09-17 Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα

Country Status (21)

Country Link
US (1) US7875605B2 (enExample)
EP (1) EP1581492B1 (enExample)
JP (1) JP4559230B2 (enExample)
KR (1) KR100818508B1 (enExample)
CN (2) CN101544592B (enExample)
AT (1) ATE401307T1 (enExample)
AU (1) AU2003237599B2 (enExample)
BR (2) BRPI0318799B8 (enExample)
CA (1) CA2509982C (enExample)
CY (1) CY1108786T1 (enExample)
DE (1) DE60322266D1 (enExample)
DK (1) DK1581492T3 (enExample)
EA (1) EA011320B1 (enExample)
ES (1) ES2310243T3 (enExample)
MX (1) MXPA05005701A (enExample)
NO (2) NO330341B1 (enExample)
NZ (2) NZ540840A (enExample)
PT (1) PT1581492E (enExample)
SI (1) SI1581492T1 (enExample)
WO (1) WO2004048330A1 (enExample)
ZA (1) ZA200504043B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694129B2 (ja) * 2002-02-12 2011-06-08 ナームローゼ・フエンノートチヤツプ・オルガノン 中枢神経系疾患の治療において有用な１−アリールスルホニル−３−置換インドール及びインドリン誘導体
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
MXPA06007415A (es) 2004-01-02 2007-01-26 Suven Life Sciences Ltd Inden [2, 1a] indenos e isoindol [2,1-a] indoles novedosos.
RU2422442C2 (ru) 2005-07-29 2011-06-27 Ф. Хоффманн-Ля Рош Аг Производные индол-3-ил-карбонил-пиперидина и пиперазина
CA2618636C (en) 2005-08-12 2011-01-18 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands
WO2007020653A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
KR101250820B1 (ko) 2005-08-16 2013-04-04 수벤 라이프 사이언시스 리미티드 개선된 로사르탄 제조 방법
EP2121602B1 (en) * 2007-01-08 2015-03-18 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
JP2010515674A (ja) * 2007-01-08 2010-05-13 スベン ライフ サイエンシズ リミティド ５−（ヘテロシクリル）アルキル−ｎ−（アリールスルホニル）インドール化合物および５−ｈｔ６リガンドとしてのそれらの使用
CA2683124C (en) 2007-05-03 2012-09-25 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
WO2008144263A1 (en) * 2007-05-18 2008-11-27 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
AU2008315309B2 (en) 2007-10-26 2011-06-09 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
ES2424036T3 (es) 2008-09-17 2013-09-26 Suven Life Sciences Limited Compuestos de amina de arilsulfonamida y su uso como ligandos de 5-HT6
US8912220B2 (en) * 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
US8153680B2 (en) * 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
MX2012007783A (es) 2010-01-05 2012-10-03 Suven Life Sciences Ltd Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
CN102093149A (zh) * 2010-12-08 2011-06-15 天津理工大学 一种促进氰基快速水解制备羧酸类化合物的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
WO2015083179A1 (en) * 2013-12-02 2015-06-11 Suven Life Sciences Limited Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
BR112017002921B1 (pt) 2014-08-16 2023-03-28 Suven Life Sciences Limited Composto metabólito ativo de monohidrato dimesilato de 1-[(2- bromofenil)sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1h-indola,processo para a preparação do composto e composição farmacêutica
DK3458039T3 (da) * 2016-05-18 2020-09-14 Suven Life Sciences Ltd Tripelkombination af rene 5-ht6-receptorantagonister, acetylcholinesterasehæmmere og nmda-receptorantagonist
DK3458040T3 (da) * 2016-05-18 2021-05-03 Suven Life Sciences Ltd Kombination af rene 5-ht6-receptorantagonister med nmda-receptorantagonist
CA3023819C (en) * 2016-05-18 2019-10-22 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
HRP20211092T1 (hr) * 2016-10-03 2021-10-15 Suven Life Sciences Limited Farmaceutske kompozicije antagonista 5-ht6
CN107174586B (zh) * 2017-02-21 2020-08-11 中国科学院昆明植物研究所 以芦竹碱衍生物为活性成分的药物组合物及其应用
JP6959371B2 (ja) * 2017-07-03 2021-11-02 スヴェン・ライフ・サイエンシーズ・リミテッドＳｕｖｅｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
BR112022010540A2 (pt) 2019-12-02 2022-08-16 Suven Life Sciences Ltd Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência
WO2021111330A1 (en) 2019-12-02 2021-06-10 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
KR102347372B1 (ko) 2020-12-14 2022-01-07 (주)케이메디켐 신규한 인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN115504925B (zh) * 2021-06-22 2024-03-12 广东药科大学 一类ppar激动剂、其制备方法及其作为药物的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (enExample) 1969-02-26 1973-01-31
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
JPH04208263A (ja) * 1990-01-02 1992-07-29 Fujisawa Pharmaceut Co Ltd インドール誘導体およびそれらの製造法
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
ATE204275T1 (de) 1990-06-07 2001-09-15 Astrazeneca Ab Indolderivate als 5-ht1-like agonisten
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (enExample) * 1991-02-12 1995-11-21 Pfizer
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
CA2194984C (en) * 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
WO2000063203A1 (en) * 1999-04-21 2000-10-26 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1317276C (zh) 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
IL154685A0 (en) * 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
WO2002041889A2 (en) * 2000-11-24 2002-05-30 Smithkline Beecham P.L.C. Indolsulfonyl compounds useful in the treatment of cns disorders
AU2002226048A1 (en) * 2000-12-11 2002-06-24 Smith Kline Beecham Corporation Urotensin-ii receptor antagonists
ATE327232T1 (de) * 2000-12-22 2006-06-15 Wyeth Corp Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
JP2004524295A (ja) * 2001-01-26 2004-08-12 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
JP4694129B2 (ja) * 2002-02-12 2011-06-08 ナームローゼ・フエンノートチヤツプ・オルガノン 中枢神経系疾患の治療において有用な１−アリールスルホニル−３−置換インドール及びインドリン誘導体

Also Published As

Publication number Publication date
ZA200504043B (en) 2006-07-26
HK1083217A1 (en) 2006-06-30
EA011320B1 (ru) 2009-02-27
CN1720225A (zh) 2006-01-11
NO330341B1 (no) 2011-03-28
JP2006514011A (ja) 2006-04-27
EP1581492B1 (en) 2008-07-16
ES2310243T3 (es) 2009-01-01
BRPI0315959B8 (pt) 2018-01-16
DE60322266D1 (de) 2008-08-28
SI1581492T1 (sl) 2008-12-31
NO20052737L (no) 2005-08-25
NO20052737D0 (no) 2005-06-08
CN1720225B (zh) 2011-05-18
CN101544592B (zh) 2013-08-21
NO335015B1 (no) 2014-08-25
AU2003237599B2 (en) 2009-06-18
WO2004048330A8 (en) 2005-10-27
BRPI0315959C1 (pt) 2021-05-25
NZ572186A (en) 2010-02-26
JP4559230B2 (ja) 2010-10-06
AU2003237599A1 (en) 2004-06-18
PT1581492E (pt) 2008-09-19
HK1133002A1 (en) 2010-03-12
US7875605B2 (en) 2011-01-25
DK1581492T3 (da) 2008-11-10
EP1581492A1 (en) 2005-10-05
MXPA05005701A (es) 2005-08-16
NO20085054L (no) 2005-08-25
BRPI0315959B1 (pt) 2017-12-19
KR100818508B1 (ko) 2008-03-31
KR20050086868A (ko) 2005-08-30
EA200500881A1 (ru) 2005-12-29
CA2509982A1 (en) 2004-06-10
BR0315959A (pt) 2005-09-13
ATE401307T1 (de) 2008-08-15
NZ540840A (en) 2008-12-24
CA2509982C (en) 2011-11-08
CN101544592A (zh) 2009-09-30
BRPI0318799B1 (pt) 2019-06-25
US20060223890A1 (en) 2006-10-05
WO2004048330A1 (en) 2004-06-10
BRPI0318799B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1108786T1 (el) Ν-αρυλσουλφονυλ-3-υποκατεστημενα ινδολια που εχουν συναφεια υποδοχεα σεροτονινης, μεθοδος για τη παρασκευη αυτων και φαρμακευτικη συνθεση περιεχουσα αυτα
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
CY1107856T1 (el) Παραγωγα ιμιδαζολιου ως ανταγωνιστες υποδοχεα γλουταμινικου
EA200600348A1 (ru) Новые соединения
CY1108770T1 (el) Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων
BRPI0316895B8 (pt) composto, processo para a preparação do composto, composição farmacêutica e uso do composto
AR028817A1 (es) Compuestos derivados de la 1-arenosulfonil-2-arilo-pirrolidina, su empleo, un procedimiento para obtenerlos y medicamentos que los contienen
DE60302157D1 (de) Opioidrezeptorantagonisten
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
AR027644A1 (es) Compuestos de piridacinil fenil hidrazona, composicion farmaceutica que lo comprende y metodo para el tratamiento de una falla del corazon congestiva quelo emplea
ATE343580T1 (de) Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen
NO20031841L (no) Triazolderivater og farmasöytiske preparater inneholdende disse
NO20044473L (no) Ikke-steroidal progesteron reseptor modulatorer
CA2423820A1 (fr) Nouveaux derives d'indoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TH60904A (th) ไซโคลอัลคาโนอินโดลที่ถูกแทนที่ด้วยฟลูออโร และการใช้ของสิ่งนี้เป็นแอนตะโกนิสท์ตัวรับโพรสตาแกลนดิน d2